Opportunities and challenges surrounding financial models for high-investment medications: A survey of access decision-makers and employers
As an increasing number of cell and gene therapies are US Food and Drug Administration approved, health care stakeholders are attempting to strike a balance between patient access to innovative treatments and overall affordability. Read about the survey by Precision’s Erin Lopata, Christopher Terrone and Ami Gopalan to understand how access decision-makers and employers are using innovative financial models to support coverage of high-investment medications.
